Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells

Chimeric antigen receptor (CAR) T-cell immunotherapy still faces many challenges in the treatment of solid tumors, one of which is T-cell dysfunction or exhaustion. Immunomodulator lenalidomide may improve CAR T-cell function. In this study, the effects of lenalidomide on CAR T-cell functions (cytot...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Transplant
Autors principals: Wang, Zhixiong, Zhou, Guomin, Risu, Na, Fu, Jiayu, Zou, Yan, Tang, Jiaxing, Li, Long, Liu, Hui, Liu, Qian, Zhu, Xuekai
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2020
Matèries:
Cancer Pharmacogenomics and Target Therapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7784582/
https://ncbi.nlm.nih.gov/pubmed/32967454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0963689720920825
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars